177Lu-DOTATATE for Recurrent Meningioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

April 14, 2027

Study Completion Date

December 22, 2028

Conditions
Recurrent Meningioma
Interventions
DRUG

Local standard of Care

According to local standard practice, treatment or no treatment in the control arm is left to the investigator's discretion.

DRUG

177Lu-DOTATATE

Intravenous injection of 177Lu-DOTATATE

Trial Locations (12)

1090

RECRUITING

Universitaetskliniken der Uni Wien - Universitaetsklinikum Wien - AKH unikliniken, Vienna

6020

RECRUITING

A.O Landeskrankenhaus - Innsbruck Universitaetsklinik, Innsbruck

6500

NOT_YET_RECRUITING

Oncology Institute of Southern Switzerland (IOSI) - Ospedale San Giovanni, Bellinzona

7030

RECRUITING

St Olavs University Hospital - St. Olavs Hospital, Trondheim University Hospital, Trondheim

8091

NOT_YET_RECRUITING

UniversitaetsSpital Zurich - Neurology Clinic, Zurich

28041

RECRUITING

Hospital Universitario 12 De Octubre, Madrid

35042

RECRUITING

Centre Eugene Marquis, Rennes

54511

RECRUITING

CHRU de Nancy - Hopitaux De Brabois, Vandœuvre-lès-Nancy

69008

RECRUITING

Centre Leon Berard, Lyon

94805

RECRUITING

Gustave Roussy, Villejuif

0379

RECRUITING

Oslo University Hospital - Radiumhospitalet, Oslo

08035

RECRUITING

Vall D Hebron - Hospital Universitari Vall d'Hebron -Vall d'Hebron Institut Oncologia, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT06326190 - 177Lu-DOTATATE for Recurrent Meningioma | Biotech Hunter | Biotech Hunter